Developer docs
API playgroundTry for free, no card

Search company profiles

Tarsier Pharma

Full company profile

uuid0003lc2

Namestring
Tarsier Pharma
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Tarsier Pharma is a late clinical-stage pharmaceutical company headquartered in Haifa, Israel, focused on developing treatments for autoimmune and inflammatory ocular diseases, with an emphasis on the panuveitis treatment market. Founded in 2016, the company operates with a lean team of 1-10 employees and is led by founder and CEO Daphne Haim-Langford, supported by COO Zohar Milman and VP of Clinical Affairs Emilee Fulcher. The specific product portfolio, candidate molecule names, mechanism of action, and clinical trial details are not disclosed in available sources.

The company has historically funded its operations through a combination of strategic and non-dilutive capital, including a $3 million investment from Sun Pharmaceutical in September 2018 and a $2.4 million Horizon 2020 grant in September 2019, bringing total disclosed funding to approximately $5.4 million. Tarsier Pharma remains a privately held company but filed for a proposed initial public offering on the New York Stock Exchange on April 21, 2026, signaling an intent to broaden its capital base ahead of further clinical or commercial milestones. The company does not yet generate product revenue and operates in a global panuveitis treatment market estimated at $4.31 billion in 2025 and projected to reach $10.68 billion by 2035 at a 9.5% CAGR.

As a pre-commercial biotech, Tarsier Pharma's business model is currently anchored on R&D execution, clinical development, and capital formation rather than recurring product sales. Pricing, go-to-market strategy, and patient access pathways have not been disclosed, consistent with an asset that has not yet reached regulatory approval or commercialization. The proposed US listing represents the most significant strategic inflection point to date and is likely intended to finance pivotal trials, regulatory submissions, and eventual market entry in autoimmune and inflammatory ocular disease indications.

Short descriptiontext

Tarsier Pharma is a late clinical-stage Israeli pharmaceutical company developing treatments for autoimmune and inflammatory ocular diseases, particularly panuveitis. Led by founder-CEO Daphne Haim-Langford, the Haifa-based firm filed for a proposed NYSE IPO in 2026.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHaifa, Israel
HQ citystring
Haifa
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
ophthalmic therapeutics, ocular inflammation drugs, autoimmune disease treatment, panuveitis therapeutics, clinical-stage biopharmaceuticals
Industry2 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGACAK
Clinical Trial Pharmacy & IMP Management at Site
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Pharmaceuticals
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tarsier Pharma is a late clinical-stage pharmaceutical company that develops therapeutic treatments for autoimmune and inflammatory ocular diseases, with a specific focus on panuveitis. The company has not yet launched a commercial product, and its website was inaccessible at the time of data collection. It is preparing for a public listing on the New York Stock Exchange.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Tarsier Pharma is a pharmaceutical company operating in the panuveitis treatment market, with an IPO filing pending on the NYSE. The available source data does not provide details on the company's specific product portfolio, product names, or service offerings.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tarsier Pharma

Ophthalmic Pharmaceuticalstarsiuspharma.com

Tarsier Pharma is a late clinical-stage Israeli pharmaceutical company developing treatments for autoimmune and inflammatory ocular diseases, particularly panuveitis. Led by founder-CEO Daphne Haim-Langford, the Haifa-based firm filed for a proposed NYSE IPO in 2026.

What Tarsier Pharma does

Tarsier Pharma is a late clinical-stage pharmaceutical company headquartered in Haifa, Israel, focused on developing treatments for autoimmune and inflammatory ocular diseases, with an emphasis on the panuveitis treatment market. Founded in 2016, the company operates with a lean team of 1-10 employees and is led by founder and CEO Daphne Haim-Langford, supported by COO Zohar Milman and VP of Clinical Affairs Emilee Fulcher. The specific product portfolio, candidate molecule names, mechanism of action, and clinical trial details are not disclosed in available sources.

The company has historically funded its operations through a combination of strategic and non-dilutive capital, including a $3 million investment from Sun Pharmaceutical in September 2018 and a $2.4 million Horizon 2020 grant in September 2019, bringing total disclosed funding to approximately $5.4 million. Tarsier Pharma remains a privately held company but filed for a proposed initial public offering on the New York Stock Exchange on April 21, 2026, signaling an intent to broaden its capital base ahead of further clinical or commercial milestones. The company does not yet generate product revenue and operates in a global panuveitis treatment market estimated at $4.31 billion in 2025 and projected to reach $10.68 billion by 2035 at a 9.5% CAGR.

As a pre-commercial biotech, Tarsier Pharma's business model is currently anchored on R&D execution, clinical development, and capital formation rather than recurring product sales. Pricing, go-to-market strategy, and patient access pathways have not been disclosed, consistent with an asset that has not yet reached regulatory approval or commercialization. The proposed US listing represents the most significant strategic inflection point to date and is likely intended to finance pivotal trials, regulatory submissions, and eventual market entry in autoimmune and inflammatory ocular disease indications.

Tarsier Pharma firmographics

Firmographics
Name
Tarsier Pharma
Website
https://tarsiuspharma.com
Company type
Private
Founded year
2016
Operating status
Ipo
Headcount range
1–10 employees
Short description
Tarsier Pharma is a late clinical-stage Israeli pharmaceutical company developing treatments for autoimmune and inflammatory ocular diseases, particularly panuveitis. Led by founder-CEO Daphne Haim-Langford, the Haifa-based firm filed for a proposed NYSE IPO in 2026.
Ownership category
akta.pro rank

Tarsier Pharma industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGACAK
Clinical Trial Pharmacy & IMP Management at Site

Keywords

  • Ophthalmic therapeutics
  • Ocular inflammation drugs
  • Autoimmune disease treatment
  • Panuveitis therapeutics
  • Clinical-stage biopharmaceuticals

Where Tarsier Pharma is headquartered

Location

Headquarters

HQ city
Haifa
HQ country
Israel
HQ region
Middle East

Markets served

Tarsier Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Tarsier Pharma product offering

Product offering

Core offering

Tarsier Pharma is a late clinical-stage pharmaceutical company that develops therapeutic treatments for autoimmune and inflammatory ocular diseases, with a specific focus on panuveitis. The company has not yet launched a commercial product, and its website was inaccessible at the time of data collection. It is preparing for a public listing on the New York Stock Exchange.

Product overview

Tarsier Pharma is a pharmaceutical company operating in the panuveitis treatment market, with an IPO filing pending on the NYSE. The available source data does not provide details on the company's specific product portfolio, product names, or service offerings.

Differentiator

Problem solved

Functional benefit

Companies that use Tarsier Pharma

Customer profile

Ideal customer profiles1 record

Tarsier Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Tarsier Pharma partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Tarsier Pharma competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key highlights6 records

Customer concentration

Tarsier Pharma social profiles

Digital presence

Tarsier Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tarsier Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Tarsier Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tarsier Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tarsier Pharma

What does Tarsier Pharma do?

Tarsier Pharma is a late clinical-stage pharmaceutical company that develops therapeutic treatments for autoimmune and inflammatory ocular diseases, with a specific focus on panuveitis. The company has not yet launched a commercial product, and its website was inaccessible at the time of data collection. It is preparing for a public listing on the New York Stock Exchange.

Is Tarsier Pharma a public or private company?

Tarsier Pharma is a private company. It is classified as venture growth investor backed and is currently ipo.

When was Tarsier Pharma founded?

Tarsier Pharma was founded in 2016. It employs 1 to 10 people.

Where is Tarsier Pharma based?

Tarsier Pharma is headquartered in Haifa, Israel, in the Middle East region.

Does Tarsier Pharma have an API?

No public API is recorded for Tarsier Pharma.

What industry is Tarsier Pharma in?

Tarsier Pharma's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAGACAK, Clinical Trial Pharmacy & IMP Management at Site. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comTarsier Pharma files for NYSE IPO under ticker TARX By Investing.comTarsier Pharma Ltd. has filed for an initial public offering of 5,555,555 ordinary shares to list on the New York Stock Exchange under the ticker symbol TARX. The company anticipates an offering price between $8.00 and $10.00 per share, with a midpoint assumption of $9.00 per share that would raise approximately $50 million. Konik Capital Partners is serving as the sole underwriter for the offering, and no public market for the shares has existed prior to this filing.Investing.comTarsier Pharma files for NYSE IPO under ticker TARX By Investing.comTarsier Pharma Ltd. has filed for an initial public offering of 5,555,555 ordinary shares to list on the New York Stock Exchange under the ticker symbol TARX. The company anticipates an offering price between $8.00 and $10.00 per share, with a midpoint price of $9.00 that would raise approximately $50 million. Konik Capital Partners is serving as the sole underwriter for the offering, and prior to this filing no public market for the shares existed.Investing.comTarsier Pharma files for NYSE IPO under ticker TARX By Investing.comTarsier Pharma has filed for an initial public offering (IPO) on the NYSE with plans to list under the ticker TARX. The company intends to offer 5,555,555 shares at an estimated price of $8.00 to $10.00 per share, potentially raising around $50 million.AInvestTarsier Pharma upsizes IPO target to 5.6M sharesTarsier Pharma has increased its IPO target to 5.6 million shares, according to a report published on July 15, 2026. The article provides no further details on the pricing range, valuation, or reason for the upsized target. The report appears to be a brief market update with limited additional context.Renaissance CapitalIsrael-based ocular disease biotech Tarsier Pharma ups shares offered by 11% ahead of $50 million US IPOTarsier Pharma, an Israel-based Phase 3 biotech developing steroid-free therapies for inflammatory eye diseases, has increased its planned IPO size by 11%, now seeking to raise $50 million through 5.6 million shares at $8–$10 each. At the midpoint, the company would command a fully diluted market cap of $299 million, up from its initial filing of 5 million shares at the same price range. The company, founded in 2016 and based in Zichron Yaacov, plans to list on the NYSE under the symbol TARX, with Konik Capital Partners serving as sole bookrunner.The Pharma LetterTarsier Pharma sets terms for $45 million US IPOTarsier Pharma, an Israel-based biotech, announced IPO terms to raise $45 million by offering 5 million shares at $8 to $10. At the midpoint, the company would have a fully diluted market value of $294 million.Renaissance CapitalIsrael-based Phase 3 ocular diseases biotech Tarsier Pharma files for a $35 million US IPOTarsier Pharma, an Israel-based biotech, filed with the SEC for a $35 million IPO on April 21, 2026. The company develops steroid-free therapies for ocular diseases using dazdotuftide, targeting uveitis and glaucoma. It plans to list on the NYSE American under TARX.PR NewswireTarsier Pharma: New Data Reveal Sharp Rise in Vision Loss from Uveitis, Underscoring Urgent Need for Safer TreatmentsTarsier Pharma highlighted new data from independent U.S. academic studies indicating a sharp rise in uveitis-related vision loss and the limitations of current treatments like topical steroids. The company emphasized the urgent need for safer alternatives, specifically its development candidate dazdotuftide (TRS01), which is currently entering its second Phase 3 trial under an FDA Special Protocol Agreement. This press release aims to underscore the unmet medical need to support the strategic positioning of Tarsier's late-stage clinical program.PR NewswireTarsier Pharma Appoints Ashley Kline as Chief Commercial Officer, Expanding Its U.S. PresenceTarsier Pharma announced the appointment of Ashley Kline as Chief Commercial Officer on a fractional basis as the company progresses its late-stage clinical trials. Kline brings over 15 years of ophthalmology experience, having previously led the launch of Oxervate at Italy-based Dompé Farmaceutici. She will lead commercial planning for the company's pipeline, including its lead asset TRS01 (dazdotuftide eye drop), which is entering its second phase 3 trial for non-infectious uveitis following an SPA agreement with the FDA.PR NewswireTarsier Pharma Announces the Appointment of Emilee Fulcher as Vice President of Clinical AffairsTarsier Pharma, Ltd., a late-stage ophthalmic biopharmaceutical company based in Tel-Aviv, Israel, announced the appointment of Emilee Fulcher as Vice President of Clinical Affairs. Fulcher brings 20 years of pharmaceutical industry experience, including specialized expertise in ophthalmology clinical trials, and will lead the execution of the TRS01 and TRS02 clinical programs for Dazdotuftide. The company stated she will spearhead the upcoming Tarsier-04 Phase 3 trial, building on momentum from the recently completed TRS4Vision Phase 3 trial.